Skip to main content
Erschienen in: International Journal of Hematology 4/2009

01.11.2009 | Case Report

Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia

verfasst von: Satoshi Horino, Takeshi Rikiishi, Hidetaka Niizuma, Hiroshi Abe, Yuko Watanabe, Masaei Onuma, Yoshiyuki Hoshi, Yoji Sasahara, Miyako Yoshinari, Takuro Kazama, Yutaka Hayashi, Satoru Kumaki, Shigeru Tsuchiya

Erschienen in: International Journal of Hematology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Immune thrombocytopenic purpura (ITP) has been associated with several hematologic malignancies such as Hodgkin and non-Hodgkin lymphomas and chronic lymphocytic leukemia, but it is rare in children with acute lymphoblastic leukemia (ALL). Here, we report a 7-year-old girl with chronic ITP during early intensive phase of chemotherapy for ALL. She underwent splenectomy because thrombocytopenia had persisted even after treatment with intravenous immunoglobulin (IVIG), steroids, vincristine, rituximab, and anti-D antibody. After splenectomy, her platelet count had recovered, and maintenance therapy could be resumed with a support of IVIG. To our knowledge, this is the first child case of chronic ITP during chemotherapy for ALL and splenectomy was effective in this patient.
Literatur
1.
Zurück zum Zitat Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33:230–9.CrossRefPubMed Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33:230–9.CrossRefPubMed
2.
Zurück zum Zitat Martinelli G, Zinzani PL, Magagnoli M, et al. Incidence and prognostic significance of idiopathic thrombocytopenic purpura in patients with Hodgkin’s disease in complete hematological remission. Haematologica. 1998;83:669–70.PubMed Martinelli G, Zinzani PL, Magagnoli M, et al. Incidence and prognostic significance of idiopathic thrombocytopenic purpura in patients with Hodgkin’s disease in complete hematological remission. Haematologica. 1998;83:669–70.PubMed
3.
Zurück zum Zitat Rao S, Pang E. Idiopathic thrombocytopenic purpura in acute lymphoblastic leukemia. J Pediatr. 1979;94:408–9.CrossRefPubMed Rao S, Pang E. Idiopathic thrombocytopenic purpura in acute lymphoblastic leukemia. J Pediatr. 1979;94:408–9.CrossRefPubMed
4.
Zurück zum Zitat Yenicesu I, Sanli C, Güegey A. Idiopathic thrombocytopenic purpura in acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2000;17:719–20.CrossRefPubMed Yenicesu I, Sanli C, Güegey A. Idiopathic thrombocytopenic purpura in acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2000;17:719–20.CrossRefPubMed
5.
Zurück zum Zitat Kurekci AE, Atay AA, Demirkaya E, et al. Immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia and mumps. J Pediatr Hematol Oncol. 2006;28:170–2.CrossRefPubMed Kurekci AE, Atay AA, Demirkaya E, et al. Immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia and mumps. J Pediatr Hematol Oncol. 2006;28:170–2.CrossRefPubMed
6.
Zurück zum Zitat Price V, Barnes C, Canning P, et al. Immune thrombocytopenia following successful treatment of cancer in children. Pediatr Blood Cancer. 2006;46:372–6.CrossRefPubMed Price V, Barnes C, Canning P, et al. Immune thrombocytopenia following successful treatment of cancer in children. Pediatr Blood Cancer. 2006;46:372–6.CrossRefPubMed
7.
Zurück zum Zitat Campbell JK, Mitchell CA. Immune thrombocytopenia in association with acute lymphoblastic leukaemia and a haemophagocytic syndrome. Eur J Haematol. 1993;51:259–61.CrossRefPubMed Campbell JK, Mitchell CA. Immune thrombocytopenia in association with acute lymphoblastic leukaemia and a haemophagocytic syndrome. Eur J Haematol. 1993;51:259–61.CrossRefPubMed
8.
Zurück zum Zitat Kaushansky K. Thrombopoietin: a tool for understanding thrombopoiesis. J Thromb Haemost. 2003;1:1587–92.CrossRefPubMed Kaushansky K. Thrombopoietin: a tool for understanding thrombopoiesis. J Thromb Haemost. 2003;1:1587–92.CrossRefPubMed
9.
Zurück zum Zitat Saxon BR, Mody M, Blanchette VS, et al. Reticulated platelet counts in the diagnosis of acute immune thrombocytopenia purpura. J Pediatr Hematol Oncol. 1998;20:44–8.CrossRefPubMed Saxon BR, Mody M, Blanchette VS, et al. Reticulated platelet counts in the diagnosis of acute immune thrombocytopenia purpura. J Pediatr Hematol Oncol. 1998;20:44–8.CrossRefPubMed
10.
Zurück zum Zitat Kuwana M, Okazaki Y, Satoh T, et al. Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. Am J Med. 2005;118:1026–33.CrossRefPubMed Kuwana M, Okazaki Y, Satoh T, et al. Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. Am J Med. 2005;118:1026–33.CrossRefPubMed
11.
Zurück zum Zitat Berchtold P, Müller D, Beardsley D, et al. International study to compare antigen-specific methods used for the measurements of anti-platelet autoantibodies. Br J Haematol. 1997;96:477–83.CrossRefPubMed Berchtold P, Müller D, Beardsley D, et al. International study to compare antigen-specific methods used for the measurements of anti-platelet autoantibodies. Br J Haematol. 1997;96:477–83.CrossRefPubMed
12.
Zurück zum Zitat Teachey DT, Felix CA. Development of cold agglutinin autoimmune hemolytic anemia during treatment for pediatric acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2005;27:397–9.CrossRefPubMed Teachey DT, Felix CA. Development of cold agglutinin autoimmune hemolytic anemia during treatment for pediatric acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2005;27:397–9.CrossRefPubMed
13.
Zurück zum Zitat Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455–8.CrossRefPubMed Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455–8.CrossRefPubMed
14.
Zurück zum Zitat Liu B, Zhao H, Poon MC, et al. Abnormality of CD4+CD25+ regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007;78:139–43.PubMed Liu B, Zhao H, Poon MC, et al. Abnormality of CD4+CD25+ regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007;78:139–43.PubMed
15.
Zurück zum Zitat Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34:336–44.CrossRefPubMed Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34:336–44.CrossRefPubMed
16.
Zurück zum Zitat Stevens W, Koene H, Zwaginga JJ, et al. Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. Neth J Med. 2006;64:356–63.PubMed Stevens W, Koene H, Zwaginga JJ, et al. Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. Neth J Med. 2006;64:356–63.PubMed
Metadaten
Titel
Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia
verfasst von
Satoshi Horino
Takeshi Rikiishi
Hidetaka Niizuma
Hiroshi Abe
Yuko Watanabe
Masaei Onuma
Yoshiyuki Hoshi
Yoji Sasahara
Miyako Yoshinari
Takuro Kazama
Yutaka Hayashi
Satoru Kumaki
Shigeru Tsuchiya
Publikationsdatum
01.11.2009
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2009
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-009-0424-0

Weitere Artikel der Ausgabe 4/2009

International Journal of Hematology 4/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.